trending Market Intelligence /marketintelligence/en/news-insights/trending/sbzqcilhnrw_mthcviuqdg2 content esgSubNav
In This List

Roche's Tecentriq, Avastin combo cuts risk of cancer worsening or death by 26%

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Roche's Tecentriq, Avastin combo cuts risk of cancer worsening or death by 26%

Roche Holding AG's combination of Tecentriq and Avastin reduced the risk of disease worsening or death by 26% in a phase 3 study among certain patients with advanced kidney cancer.

The study, named IMmotion151, had enrolled 915 people globally and evaluated the drug combination as a first-line treatment for advanced or metastatic renal cell carcinoma.

Roche disclosed in December 2017 that the study met one of its main goals, with the results to be presented in 2018.

SNL Image

Among 362 patients with cancers expressing PD-L1 protein, the combination stopped the disease from worsening for 11.2 months, compared to 7.7 months for patients given Pfizer Inc.'s Sutent, or sunitinib.

The PD-L1 protein is present on the surface of tumor cells and has been shown to suppress the immune system.

Another goal of the trial was overall survival, the length of time from either the diagnosis or the start of treatment that the patient lives. The company said the initial observations for this goal were encouraging but still immature.